Skip to main content
Equibles
DFTX logo

DFTX · Definium Therapeutics, Inc. · Webcasts, Transcripts & Audio

Track DFTX — free

Use DFTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research DFTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$37.40 -0.20 (-0.53%) At close · Oct 2
Russell 2000 member Rebalance outlook locked
Market Cap
$5.10B
Shares
134.37M
Volume · Oct 2 1.6M Avg daily vol (3M) 2.14M

Definium Therapeutics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Definium Therapeutics, Inc. (DFTX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →
Earnings call
FY26 · Q2
2026-08-06
Definium Therapeutics, Inc. (DFTX) Q2 2026 Earnings Call
Diluted EPS
$-1.44
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-06-22
Definium Therapeutics, Inc. (DFTX) Q1 2026 Earnings Call Transcript
Confident tone DT120 Phase III Program (MDD/GAD) Pipeline Expansion (PTSD, ASD/DT402) Regulatory Progress & DEA Scheduling
Diluted EPS
$-0.71
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Definium Therapeutics, Inc. (DFTX) Q4 2025 Earnings Call Transcript
Confident tone DT120 ODT Pipeline Progress Major Depressive Disorder Program Generalized Anxiety Disorder Program
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Definium Therapeutics, Inc. (DFTX) Q3 2025 Earnings Call Transcript
Confident tone Phase III MM120 readouts in GAD and MDD ASCEND second Phase III in MDD MM402 / R-enantiomer of MDMA in autism
Diluted EPS
$-0.78
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Definium Therapeutics, Inc. (DFTX) Q2 2025 Earnings Call Transcript
Confident tone MM120 ODT Phase III trials Clinical readout timeline Phase IIb efficacy data
Diluted EPS
$-0.50
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Definium Therapeutics, Inc. (DFTX) Q1 2025 Earnings Call Transcript
Confident tone Disease Burden and Market Opportunity MM120 Phase 3 Program Execution New Chief Commercial Officer Onboarding
Diluted EPS
$-0.35
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-06
Definium Therapeutics, Inc. (DFTX) Q4 2024 Earnings Call Transcript
Confident tone MM120 Phase 3 GAD Program (Voyage and Panorama) MDD Program (Emerge) Regulatory Designations and IP
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Definium Therapeutics, Inc. (DFTX) Q3 2024 Earnings Call Transcript
Confident tone MM120 ODT in GAD (Voyage and Panorama Phase 3 studies) MM120 ODT in MDD (Emerge Phase 3 study) Clinical execution and enrollment efficiency
Diluted EPS
$-0.27
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-12
Definium Therapeutics, Inc. (DFTX) Q2 2024 Earnings Call Transcript
Confident tone MM120 Phase 3 in GAD Expansion into MDD FDA regulatory engagement
Diluted EPS
$-0.26
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Definium Therapeutics, Inc. (DFTX) Q1 2024 Earnings Call Transcript
Confident tone MM120 Phase IIb results in GAD Pipeline expansion and additional indications ODT formulation and IP
Diluted EPS
$-1.14
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Definium Therapeutics, Inc. (DFTX) Q4 2023 Earnings Call Transcript
Confident tone MM120 Phase 2b results in GAD Phase 3 development and End-of-Phase 2 meeting MM402 and R(-)-MDMA program in ASD
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Definium Therapeutics, Inc. (DFTX) Q3 2023 Earnings Call Transcript
Diluted EPS
$-0.45
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Definium Therapeutics, Inc. (DFTX) Q2 2023 Earnings Call Transcript
Diluted EPS
$-0.76
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Definium Therapeutics, Inc. (DFTX) Q1 2023 Earnings Call Transcript
Diluted EPS
$-0.65
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-09
Definium Therapeutics, Inc. (DFTX) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Definium Therapeutics, Inc. (DFTX) Q3 2022 Earnings Call Transcript
Diluted EPS
$-0.56
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Definium Therapeutics, Inc. (DFTX) Q2 2022 Earnings Call
Diluted EPS
$-0.60
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-16
Definium Therapeutics, Inc. (DFTX) Q1 2022 Earnings Call
Diluted EPS
$-0.66
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-28
Definium Therapeutics, Inc. (DFTX) Q4 2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–19 of 19 webcasts
Key facts CIK 1813814 CUSIP 24477V105 13F (30d) 7 filings 7 filers Visit website Investor relations